MedTrace Logo

Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy

NCT06749639 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-12-31

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of PUMCH-E101 injection in subjects with RDH12 retinopathy.

Conditions

Interventions

GENETIC

PUMCH-E101 Injection（Low dose）

Single intravitreal injection

GENETIC

PUMCH-E101 Injection（High dose）

Single intravitreal injection

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Ruifang Sui, MD, PhD · Peking Union Medical College Hospital, Department of Ophthalmology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
8 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2027-12-31
Completion
2030-01-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06749639 on ClinicalTrials.gov